BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 8794181)

  • 1. Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality.
    Pearson HA
    Adv Pediatr; 1996; 43():309-34. PubMed ID: 8794181
    [No Abstract]   [Full Text] [Related]  

  • 2. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
    Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW
    N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
    Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea therapy in thalassemia.
    Loukopoulos D; Voskaridou E; Stamoulakatou A; Papassotiriou Y; Kalotychou V; Loutradi A; Cozma G; Tsiarta H; Pavlides N
    Ann N Y Acad Sci; 1998 Jun; 850():120-8. PubMed ID: 9668534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactivation of fetal hemoglobin in patients with beta-thalassemia.
    Olivieri NF
    Semin Hematol; 1996 Jan; 33(1):24-42. PubMed ID: 8714583
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia.
    Musallam KM; Taher AT; Cappellini MD; Sankaran VG
    Blood; 2013 Mar; 121(12):2199-212; quiz 2372. PubMed ID: 23315167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversing ontogeny.
    Bunn HF
    N Engl J Med; 1993 Jan; 328(2):129-31. PubMed ID: 7677964
    [No Abstract]   [Full Text] [Related]  

  • 8. Hydroxyurea for sickle cell anemia.
    Naina HV; Harris S
    N Engl J Med; 2008 Jul; 359(1):98; author reply 98-9. PubMed ID: 18596283
    [No Abstract]   [Full Text] [Related]  

  • 9. Pathophysiologically based drug treatment of sickle cell disease.
    Steinberg MH
    Trends Pharmacol Sci; 2006 Apr; 27(4):204-10. PubMed ID: 16530854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing fetal hemoglobin in sickle cell disease: comparisons of 5-azacytidine (subcutaneous or oral) with hydroxyurea.
    Dover GJ; Charache S; Boyer SH
    Trans Assoc Am Physicians; 1984; 97():140-5. PubMed ID: 6085527
    [No Abstract]   [Full Text] [Related]  

  • 11. DNA hypomethylation therapies and hemoglobin disorders. [An interview with Hassana Fathallah by H&O].
    Fathallah H
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):806-8. PubMed ID: 19194363
    [No Abstract]   [Full Text] [Related]  

  • 12. Hemoglobin switching protocols in thalassemia. Experience with sodium phenylbutyrate and hydroxyurea.
    Dover GJ
    Ann N Y Acad Sci; 1998 Jun; 850():80-6. PubMed ID: 9668530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
    Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to hydroxyurea among Kuwaiti patients with sickle cell disease and elevated baseline HbF levels.
    Adekile A; Menzel S; Gupta R; Al-Sharida S; Farag A; Haider M; Akbulut N; Mustafa N; Thein SL
    Am J Hematol; 2015 Jul; 90(7):E138-9. PubMed ID: 25851995
    [No Abstract]   [Full Text] [Related]  

  • 15. Exposure to hydroxyurea during pregnancy in sickle-beta thalassemia: a report of 2 cases.
    Italia KY; Jijina FF; Chandrakala S; Nadkarni AH; Sawant P; Ghosh K; Colah RB
    J Clin Pharmacol; 2010 Feb; 50(2):231-4. PubMed ID: 19797538
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacologic induction of fetal hemoglobin synthesis: cellular and molecular mechanisms.
    Yang YM; Pace B
    Pediatr Pathol Mol Med; 2001; 20(1):87-106. PubMed ID: 12673846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological induction of fetal hemoglobin synthesis using histone deacetylase inhibitors.
    Cao H
    Hematology; 2004 Jun; 9(3):223-33. PubMed ID: 15204104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia.
    Atweh GF; Loukopoulos D
    Semin Hematol; 2001 Oct; 38(4):367-73. PubMed ID: 11605172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological induction of fetal hemoglobin: Why haven't we been more successful in thalassemia?
    Fathallah H; Sutton M; Atweh GF
    Ann N Y Acad Sci; 2005; 1054():228-37. PubMed ID: 16339670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic stimulation of Hb F in patients with sickle cell anemia.
    Galanello R; Veith R; Papayannopoulou T; Stamatoyannopoulos G
    Prog Clin Biol Res; 1985; 191():433-45. PubMed ID: 2413479
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.